All News
Adherence to ETN/MTX is Greater Than Triple DMARD Therapy
Rheumatoid management hinges on choosing your best therapies first.
Read ArticleAustralia Allows Pharmacy Substitution with Biosimilars Without Notice
Biosimilars are copies of the biologic medicines used to treat inflammatory and immunologic conditions such as rheumatoid arthritis, multiple sclerosis and cancer- potentially at lower costs.
Read ArticleNICE Judges Apremilast Less Cost Effective than TNF Inhibitors
The National Institute for Heath and Care Excellence has turned down Otezla for coverage under the U.K. healthcare system for psoriatic arthritis.
Read ArticleFrequency of Infliximab Infusion Reactions
A Canadian registry shows that in community-based infusion clinics, infusion reactions to IFX are uncommon and mild to moderate in nature.
Read ArticleDSB: EULAR 2015 Safety Reports
Biologic Use Curtails Sepsis Events. An analysis of the German biologics register, RABBIT, examined the effect of current biologic therapy on future risk of sepsis (#OP0161).
Read ArticleThe Risk of Uveitis in AS Treated with TNF Blockers
Claims data analysis of 2115 ankylosing spondylitis patients without uveitis who started TNF inhibitor therapy revealed that the median time to the onset of uveitis was longest for those taking adalimumab (243 days), followed by etanercept (182 days) and infliximab (144 days). 
Read ArticleExpanding Global Biosimilar Market
Between 2010 and 2013, $95 billion in branded pharmaceutical patents will have expired, leading to significantly higher sales opportunities for those manufacturing generics and biosimilars.
Read ArticleThe EULAR 2015 Report- Friday
These abstracts and presentations were presented 12 June at the EULAR 2015 annual meeting.
Read ArticleThe EULAR 2015 Report - Wednesday
EULAR 2015 started the afternoon of Wednesday June 10th.
Read ArticleNonadherence to Self-Injected Biologics is High
Researchers from the University of Manchester investigated self-reported adherence to biologic treatment in RA and found that 41% of patients were non-adherent to adalimumab therapy at least once, and 23% were nonadherent overall. http://bit.ly/1KA2
Read ArticleAmgen & Abbvie Increase the Price of TNF Inhibitors
The manufacturers of the 2 best selling TNF inhibitors, Enbrel and Humira, have announced a 9.9% price increase of May 1st. The current average price of Enbrel is $42,000 per annum.
Read Article
A Microneedle Pill as an Alternative to Injectable Drug
Carl Schoellhammerhas just won the Lemelson-MIT National Collegiate Student Prize for his invention - the microneedle pill.
Read ArticleAdalimumab Gets FDA Orphan Drug Status for Use in Hidradenitis Suppurativa
The FDA has granted adalimumab (Humira) orphan drug designation for the investigational treatment of moderate-to-severe hidradenitis suppurativa (HS) (Hurley Stage II and Hurley Stage III disease).
Read ArticleEconomic Impact of Biosimilars
According to the Federal Trade Commission biosimilars have the potential to save the U.S. healthcare system $250 billion through 2022.
Read ArticleHepatotoxicity and TNF Inhibitors
Hepatic enzyme elevations with TNF inhibitor use is not uncommon.
Read ArticleRA Compliance Undermines Treatment Success
Researchers at MD Anderson Cancer Center in Houston prospectively studied 107 RA patients with regard to oral medication (DMARDs, steroids) adherence. They report that adherence was low, ranging from 58-71% overall.
Read ArticleZoster Risk is Similar Among Different MOA Biologics
The risk of new H zoster infection was studied among nearly 30,000 new biologic starts and compared rates seen with abatacept, adalimumab, rituximab, infliximab, etanercept, tocilizumab, certolizumab or golimumab initiation.
Read ArticleIs There a Standout When Comparing Novel Therapies?
Randomized clinical trials are needed to show efficacy and safety, and are needed to back up the claims and indications for a particular drug. The issue of treatment choice has become challenging, especially when choosing to start or augment therapy.
Read ArticleDRESS Trial Shows TNFi Dose Reduction is Possible - Without Major Flares
Can TNF inhibitor therapy be withdrawn in RA patients who are in remission? The DRESS trial reports the results of randomized trial of 180 RA patients taking either etanercept or adalimumab. Patients were randomly assigned to either usual care (no dose reduction) or a stepwise increase
Read Article